Viropil contains dolutegravir, lamivudine, and tenofovir disoproxil fumarate as its active components. It is a fixed-dose combination pill (50 mg / 300 mg / 300 mg) used in the treatment of human immunodeficiency virus (HIV) infection. In Hong Kong, the product is classified as a prescription medication and is regulated by the Department of Health.
Viropil combines three agents that target different steps of the HIV life cycle:
Onset of virologic effect typically occurs within days, with peak plasma concentrations reached 2-4 hours after oral intake. The half-life of dolutegravir (approximately 14 hours) supports once-daily dosing.
Viropil is approved in Hong Kong for the treatment of HIV-1 infection in adults. It is indicated for patients who are antiretroviral-naïve or who are switching from a stable regimen with no prior resistance to any of its components. The combination is intended to simplify therapy and improve adherence by supplying three agents in a single pill.
Ideal candidates are adults with confirmed HIV-1 infection who have no documented resistance to the three ingredients and who do not have conditions that contraindicate any component.
Absolute contraindications
Relative contraindications
Special populations
If any serious reaction such as severe rash, jaundice, or signs of renal failure occurs, seek immediate medical attention.
Patients should provide a complete medication list-including over-the-counter drugs, supplements, and herbal products-to their prescriber before starting Viropil.
Effective HIV management with Viropil includes routine laboratory and clinical assessments:
This article provides educational information about Viropil and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Viropil is a complete regimen and is generally not combined with additional antiretrovirals. Adding other agents may increase toxicity risk or cause drug interactions; any changes should be supervised by an HIV specialist.
A mild rash is often self-limited, but a widespread or severe rash may signal an allergic reaction. Stop the medication and seek medical evaluation promptly.
Viropil can be taken at any time of day, provided the same time is used daily to maintain consistent drug levels. Consistency supports adherence.
Viropil combines an integrase inhibitor with two NRTIs, similar to other fixed-dose combinations. Differences lie in the NRTI backbone (tenofovir disoproxil fumarate vs. tenofovir alafenamide) and potential renal or bone safety considerations.
Yes, but keep the medication in its original packaging with a copy of the prescription. Check the destination country’s import regulations for prescription drugs before travel.
Dolutegravir does not reduce the efficacy of hormonal contraceptives. However, any medication changes should be discussed with a healthcare provider to ensure continued protection.
No specific dietary restrictions are required. High-calcium foods or supplements do not interfere with absorption, but maintain a balanced diet to support overall health.
Baseline and periodic eGFR measurements are essential. If eGFR falls below 30 mL/min, tenofovir disoproxil fumarate may need to be discontinued or replaced with an alternative NRTI.
Yes. Both lamivudine and tenofovir have activity against hepatitis B virus, providing dual benefit. Discontinuation without an alternative HBV-active agent can trigger hepatic flare.
Missing occasional doses may reduce viral suppression and increase the chance of resistance, especially to dolutegravir. Promptly contacting a healthcare provider after missed doses is advisable.
